Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34259 | 0.90 | GAA (0.48) | GAAMAPT | |
| Water SCHEMBL4672877 | 0.88 | GAA (0.46) | GAAMAPT | |
| Bromide SCHEMBL10654286 | 0.88 | GAA (0.46) | GAAMAPT | |
| Ammonia Solution, Strong SCHEMBL4151802 | 0.88 | GAA (0.46) | GAAMAPT | |
| SCHEMBL8654087 | 0.88 | GAA (0.46) | GAAMAPT | |
| Iodide SCHEMBL12466756 | 0.88 | GAA (0.46) | GAAMAPT | |
| Hydrochloric Acid SCHEMBL160640 | 0.88 | GAA (0.46) | GAAMAPT | |
| Water SCHEMBL16465946 | 0.88 | GAA (0.46) | GAAMAPT | |
| SCHEMBL1787947 | 0.88 | GAA (0.46) | GAAMAPT | |
| SCHEMBL29181632 | 0.88 | GAA (0.46) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518755-B2 | Stable solutions of multicyclic antidepressants | LEYDEN TECHNOLOGIES B.V. (NL) | 2022-12-06 | — | — | US | disclosed |
| US-20200290999-A1 | Stable solutions of multicyclic antidepressants | LEYDEN TECHNOLOGIES B.V. (NL) | 2020-09-17 | — | — | US | disclosed |
| EP-3691651-A1 | STABLE SOLUTIONS OF MULTICYCLIC ANTIDEPRESSANTS | Leyden Technologies B.V. (NL) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019068859-A1 | STABLE SOLUTIONS OF MULTICYCLIC ANTIDEPRESSANTS | LEYDEN TECHNOLOGIES B.V. (NL) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518755-B2 | Stable solutions of multicyclic antidepressants | TPH1, BDNF, TPH2 | GAA 2193/4885MAPT 225/4885HTR2C 7/4885 |
| US-20200290999-A1 | Stable solutions of multicyclic antidepressants | TPH1, BDNF, TPH2 | GAA 2193/4885MAPT 225/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.